Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Immvira
company
About
Immvira’s scientific objectives are based on numerous experimental designs of oHSV and outcomes of clinical trials.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series C
- Industries
- Clinical Trials
- Founded date
- Jan 1, 2015
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$15M
Immvira has raised a total of
$15M
in funding over 2 rounds. Their latest funding was raised on
Oct 26, 2022 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 26, 2022 | Series C | — | 2 | — | — | Detail |
| Jan 31, 2019 | Series A | $15M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
Immvira is funded by 3 investors.
Lifebay
and Unifortune
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
Unifortune
|
— | Series C |
|
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
